15 Jan Caszyme
Giedrius Gasiunas, Ph.D., CEO
April 29 | 1:45pm | Salone dei Cavalieri, Section 1
Vilnius, Lithuania
(Private)
Caszyme is a Lithuania-based gene editing company which combines its deep experience and dynamic platform to deliver world class CRISPR solutions. Caszyme was established in 2017 by scientists, who were first to demonstrate that CRISPR-Cas9 can be used to generate double strand DNA breaks. Over the last 8 years, Caszyme has rapidly advanced its excellence and capabilities as an enabling expert partner in CRISPR gene editing solutions, collaborating with multiple life science organizations aiming to enter the CRISPR field or expand their gene editing capabilities. Also, Caszyme has developed a platform of unique CRISPR nucleases, including novel Cas12l, available for licensing. This enables Caszyme partners across various industries effectively apply CRISPR gene editing technology and tools for their market-ready products. Currently, in the therapeutics field Caszyme aims to develop safer and more compact gene editing tools for treating genetic eye diseases in vivo.
